- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6239
Provisional Schedule
- Committee meeting:
- 16 September 2026
- Expected publication:
- 11 November 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- Bristol Myers Squibb
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Addenbrookes Liver Transplant Association
- Black Health Agency for Equality
- British Liver Trust
- Cancer Black Care
- Cancer 52
- GUTS UK
- Haemochromatosis UK
- Helen Rollason Cancer Charity
- Hepatitis B Foundation UK
- Hepatitis C Trust
- Independent Cancer Patients’ Voice
- Liver4Life
- LIVErNorth
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Pelican Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Anaesthetists of Great Britain & Ireland
- Association of Cancer Physicians
- Association of Surgeons of Great Britain & Ireland
- British Association of the Study of the Liver
- British Association of Surgical Oncology
- British Geriatrics Society
- British Hepatology Pharmacy Group
- British Institute of Radiologists
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society of Gastroenterology
- British Society of Interventional Radiology
- Cancer Research UK
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiologists
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AstraZeneca (durvalumab, tremelimumab)
- Bayer (sorafenib)
- Biocon Biologics (bevacizumab)
- Celltrion Healthcare (bevacizumab)
- Dr Reddy's Laboratories (bevacizumab)
- Eisai (lenvatinib)
- Organon Pharma (bevacizumab)
- Pfizer (bevacizumab)
- Roche (atezolizumab, bevacizumab)
- Sandoz (sorafenib)
- Thornton and Ross (bevacizumab, sorafenib)
- Zentiva Pharma (bevacizumab, sorafenib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Hepato-biliary Group
- Cochrane Infection Diseases Group
- Foundation for Liver Research
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 February 2026 | Invitation to participate |
| 11 September 2025 | In progress. Dear stakeholders, Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early January 2025 when we will write to you about how you can get involved. Submissions are expected in mid-March 2026. |
| 03 February 2025 | Note - Note added to the project documents |
| 11 August 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual